What the FDA labels say about taking them together
Atazanavir and mifepristone
Mifepristone's FDA label of September 25, 2025 names atazanavir in its drug interactions section; the atazanavir labels PlainMeds reads (2) do not name mifepristone. The mifepristone label: “… CYP3A, such as itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir, amprenavir, fosamprenavir, clarithromycin, conivaptan, lopinavir/ritonavir, posaconazole, saquinavir, telithromycin, or …”
Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the mifepristone FDA label on DailyMed (effective September 25, 2025, Corcept Therapeutics Incorporated).
What does the atazanavir label say about mifepristone?
Atazanavir's label (effective August 6, 2025) and its 1 other brand-application label do not name mifepristone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
What does the mifepristone label say about atazanavir?
Mifepristone label, drug interactionsKetoconazole and other strong inhibitors of CYP3A, such as itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir, amprenavir and fosamprenavir, clarithromycin, conivaptan, lopinavir /ritonavir, posaconazole, saquinavir, telithromycin, or voriconazole may increase exposure to mifepristone.
Mifepristone label, warnings and precautionsMifepristone should be used with caution in patients taking ketoconazole and other strong inhibitors of CYP3A, such as itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir, amprenavir, fosamprenavir, clarithromycin, conivaptan, lopinavir/ritonavir, posaconazole, saquinavir, telithromycin, or voriconazole, as these could increase the concentration of mifepristone in the blood.
Source: FDA drug label (Mifepristone), Corcept Therapeutics Incorporated, effective September 25, 2025 (SPL set 63c068cd-9370-460f-829b-70e8c7ebe91e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir | Mifepristone | |
|---|---|---|
| Labeled for | HIV | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $2.23 per capsule 300 mg capsule | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once